Biogen signs an exclusive licensing agreement with Alteogen to develop subcutaneous formulations of two biologics using ALT-B4 technology in a deal worth up to $579 million including milestones.
Written By: Pharmacally Medical News Desk
Biotechnology company Biogen has entered into an exclusive licensing agreement with South Korea–based Alteogen Inc. to develop and commercialize subcutaneous (SC) formulations of two biologic medicines using Alteogen’s proprietary hyaluronidase technology.
Under the agreement, Biogen will obtain exclusive rights to develop SC formulations for two biologic products using ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase derived from Alteogen’s Hybrozyme™ technology platform.
Financial terms of the deal include an upfront payment of $20 million to Alteogen. The company will also receive an additional $10 million if development begins on a second product. In total, Alteogen is eligible to earn up to $549 million in development, regulatory, and commercial milestone payments tied to the two products. Following commercialization, the company will receive royalties based on net sales.
The agreement also provides Biogen with an option to include a third biologic product under the same technology platform in the future.
ALT-B4 is designed to enable biologic medicines that are typically administered through intravenous (IV) infusion to be reformulated as subcutaneous injections, which are generally faster and more convenient for patients. The enzyme temporarily breaks down hyaluronan in the extracellular matrix, allowing improved dispersion and absorption of co-administered therapies.
Commenting on the partnership, Alteogen CEO Tae-Yon Chun said Biogen’s strong research and development capabilities make it an ideal partner to advance innovative therapies and expand patient access to more convenient treatment options.
Reference
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics, 26 March 2026, Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics – 뉴스 – 알테오젠 ALTEOGEN